TSHA
NASDAQ · Biotechnology
Taysha Gene Therapies Inc
$5.02
-0.14 (-2.71%)
Financial Highlights (FY 2026)
Revenue
9.97M
Net Income
-111,076,659
Gross Margin
—
Profit Margin
-1,115.3%
Rev Growth
+57.5%
D/E Ratio
0.20
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 50.0% | 50.0% |
| Operating Margin | -1,130.6% | -1,017.6% | 20.3% | 19.2% |
| Profit Margin | -1,115.3% | -1,059.5% | 16.9% | 15.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 9.97M | 6.33M | 242.81M | 217.48M |
| Gross Profit | — | — | 121.41M | 108.74M |
| Operating Income | -112,731,526 | -64,405,747 | 49.27M | 41.66M |
| Net Income | -111,076,659 | -63,460,288 | 41.01M | 33.31M |
| Gross Margin | — | — | 50.0% | 50.0% |
| Operating Margin | -1,130.6% | -1,017.6% | 20.3% | 19.2% |
| Profit Margin | -1,115.3% | -1,059.5% | 16.9% | 15.3% |
| Rev Growth | +57.5% | +57.5% | -6.9% | +4.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 139.90M | 139.90M | 297.64M | 350.89M |
| Total Equity | 684.46M | 684.46M | 514.03M | 439.34M |
| D/E Ratio | 0.20 | 0.20 | 0.58 | 0.80 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -111,435,076 | -67,202,007 | 60.77M | 54.08M |
| Free Cash Flow | — | — | 46.40M | 32.89M |